ReviewAsia-Pacific journal of oncology nursing2025
Risk factors associated with immune-related severe adverse events in patients with cancer: A scoping review.
Review in Asia-Pacific journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.BMC cancer · 2025Article
- MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation.BMC gastroenterology · 2025Article
- Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Increasing reports of immune-related severe adverse events (ir-SAEs) among patients with cancer treated with immune checkpoint inhibitors (ICIs) have raised significant concerns regarding patient safety. Although considerable research has addressed immune-related adverse events (irAEs), the risk factors specifically associated with ir-SAEs remain less well defined. This study aims to identify and synthesize the risk factors contributing to ir-SAEs in patients with cancer. Methods: Adhering to the Joanna Briggs Institute scoping review guidelines, we conducted a comprehensive literature search across multiple databases including PubMed, Embase, Web of Science, ProQuest Dissertations and Theses, Clinical Trials, China Biomedical Literature Database, CNKI, Wanfang Database, and VIP Database. Studies published from the inception of each database up to 28 January 2024 were considered. Two independent reviewers screened the literature and extracted the relevant data. Results: A total of 41 studies were included, comprising 20 retrospective case-control studies, 9 retrospective cohort studies, 8 prospective cohort studies, and 4 meta-analyses. The analysis identified three primary categories of risk factors: demographic factors, disease-related factors, and laboratory examination-related factors. Conclusions: A diverse range of risk factors is associated with ir-SAEs in patients with cancer. Enhancing the education of clinical oncology nurses regarding these risk factors may facilitate early identification and management of high-risk groups, thereby improving patient safety. Given the observed inconsistencies among studies, further research is warranted to elucidate risk factors with high predictive value for ir-SAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.